Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: Meta-analysis of 5 trials

Journal of Hepatology

Volumn 61, Issue 2, 2014, Pages 200-209

  Vierling, John M ^a   Zeuzem, Stefan ^b   Poordad, Fred ^c   Bronowicki, Jean Pierre ^d   Manns, Michael P ^e   Bacon, Bruce R ^f   Esteban, Rafael ^g   Flamm, Steven L ^h   Kwo, Paul Y ⁱ   Pedicone, Lisa D ^j   Deng, Weiping ^j   Dutko, Frank J ^j   Dinubile, Mark J ^j   Koury, Kenneth J ^j   Helmond, Frans A ^j   Wahl, Janice ^j   Bruno, Savino ^k  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d UNIVERSITÉ DE LORRAINE   (France)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j MERCK RESEARCH LABORATORIES   (United States)

^k FATEBENEFRATELLI HOSPITAL   (Italy)

more..

Author keywords

Chronic HCV; Cirrhosis; Hepatitis C

Indexed keywords

BOCEPREVIR; HEMOGLOBIN; PEGINTERFERON; RIBAVIRIN; SERUM ALBUMIN; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; PEGINTERFERON ALPHA2A; PROLINE; RECOMBINANT PROTEIN;

ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; BODY MASS; CHILL; DECOMPENSATED LIVER CIRRHOSIS; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; FATIGUE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; INFECTION; LIVER CIRRHOSIS; LIVER FIBROSIS; LYMPHOCYTE COUNT; META ANALYSIS; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPSIS; SYSTEMATIC REVIEW; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRUS LOAD; ADULT; AGED; ANALOGS AND DERIVATIVES; CHRONIC HEPATITIS C; COMPLICATION; DRUG COMBINATION; FEMALE; MALE; MIDDLE AGED; STATISTICAL MODEL; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROLINE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL;

EID: 84904741728     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.03.022     Document Type: Article

References (17)

1. M. Bourliere, A. Wendt, H. Fontaine, C. Hezode, S. Pol, and J.P. Bronowicki How to optimize HCV therapy in genotype 1 patients with cirrhosis Liver Int 33 2013 46 55
2. S. Bruno, J.M. Vierling, R. Esteban, L.M. Nyberg, H. Tanno, and Z. Goodman et al. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis J Hepatol 58 2013 479 487
3. C. Hezode, H. Fontaine, C. Dorival, D. Larrey, F. Zoulim, and V. Canva et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890 J Hepatol 59 2013 434 441
4. H. Fontaine, C. Hezode, C. Dorival, D. Larrey, F. Zoulim, and V. de Ledinghen et al. SVR12 rates and safety of triple therapy including teleprevir or boceprevir in 221 cirrhotic non responders treated in the French Early Access Program (ANRS CO20-CUPIC) J Hepatol 58 2013 S27
5. B. Bacon, S. Gordon, E. Lawitz, P. Marcellin, J. Vierling, and S. Zeuzem et al. Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
6. F. Poordad, B. Bacon, S. Bruno, M. Mann, M. Sulkowski, and I. Jacobson et al. Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
7. J. Vierling, M. Davis, S. Flamm, S. Gordon, E. Lawitz, and E. Yoshida et al. Sustained virologic response (SVR) in prior peginterferon/ribavirin (PR) treatment failures after retreatment with Boceprevir (BOC) + PR: the Provide study interim results Gastroenterology 142 2012 [Supplement 1-S-931]
8. S.L. Flamm, E. Lawitz, I. Jacobson, M. Bourliere, C. Hezode, and J.M. Vierling et al. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection Clin Gastroenterol Hepatol 11 2013 81 87
9. E. Lawitz, S. Zeuzem, L. Nyberg, D. Nelson, L. Rossaro, and L. Balart et al. Boceprevir (BOC) combined with peginterferon alfa-2b/ribavirin (P/RBV) in treatment-naïve chronic HCV genotype 1 patients with compensated cirrhosis: sustained virologic response (SVR) and safety subanalyses from the anemia management study Hepatology 56 2012 216A
10. G. Garcia-Tsao, S. Friedman, J. Iredale, and M. Pinzani Now there are many (stages) where before there was one: in search of a pathophysiological classification of cirrhosis Hepatology 51 2010 1445 1449
11. A.A. Qamar, N.D. Grace, R.J. Groszmann, G. Garcia-Tsao, J. Bosch, and A.K. Burroughs et al. Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosis Hepatology 47 2008 153 159
12. J. Vierling, S. Zeuzem, F. Poordad, J. Bronowicki, M. Manns, and B. Bacon et al. Safety and efficacy of boceprevir/peginterferon/ribavirin (BOC/P/R) combination therapy for chronic HCV G1 patients with compensated cirrhosis: a meta-analysis of five phase 3 clinical trials J Hepatol 58 2013 S576 S577
13. S. Aleman, N. Rahbin, O. Weiland, L. Davidsdottir, M. Hedenstierna, and N. Rose et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis Clin Infect Dis 57 2013 230 236
14. A.J. van der Meer, B.J. Veldt, J.J. Feld, H. Wedemeyer, J.F. Dufour, and F. Lammert et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis JAMA 308 2012 2584 2593
15. T. Asselah, and P. Marcellin Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir Liver Int 34 2014 60 68
16. T.J. Liang, and M.G. Ghany Current and future therapies for hepatitis C virus infection N Engl J Med 368 2013 1907 1917
17. E. Estrabaud, M. Vidaud, P. Marcellin, and T. Asselah Genomics and HCV infection: progression of fibrosis and treatment response J Hepatol 57 2012 1110 1125